Showing results (21-30 of 187) with videos related to
Sort By:
Pageof 19
Cancer Investigation|February 8, 2025
Exclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024Daniel J Olivieri, Ajay K Gopal, Thomas S Uldrick, et al.Blood Research|May 13, 2022
Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8+ T-cells despite immune checkpoint signalingAdam M Greenbaum, Jonathan R Fromm, Ajay K Gopal, et al.Leukemia & Lymphoma|May 15, 2024
Mitigating time toxicity in lymphoma and multiple myelomaMengyang Di, Christopher T Su, Andrew J Cowan, et al.Blood|April 1, 2009
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphomaAjay K Gopal, John M Pagel, Jonathan R Fromm, et al.Cancer Genetics|March 23, 2024
Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expressionChia-Chen Ho, Kikkeri Naresh, Yajuan Liu, et al.Clinical Lymphoma, Myeloma & Leukemia|January 6, 2026
HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer CenterC Natasha Kwendakwema, Kristine F Lan, H Nina Kim, et al.Blood|May 27, 2008
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbAjay K Gopal, Oliver W Press, Shani M Wilbur, et al.Leukemia & Lymphoma|October 25, 2008
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphomaRenata Zaucha, Ted Gooley, Leona Holmberg, et al.Journal of Clinical Apheresis|February 3, 2012
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cellsAjay K Gopal, Mehdi Karami, JoAl Mayor, et al.Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphomaRyan D Cassaday, Andre Goy, Suresh Advani, et al.Pageof 19